関: methylprednisolone sodium succinate

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock
2. 頸部の疼痛または損傷がみられる小児または思春期のアスリートに対するアプローチ approach to the child or adolescent athlete with neck pain or injury
3. 小児および思春期におけるクローン病マネージメントの概要 overview of the management of crohn disease in children and adolescents
4. ステロイド用量の決定因子 determinants of glucocorticoid dosing
5. 成人における多発性硬化症の急性増悪の治療 treatment of acute exacerbations of multiple sclerosis in adults

English Journal

Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.

Sun S, Schaller J, Placek J, Duersch B.Author information Merck Manufacturing Division, Merck & Co., Inc., Whitehouse Station, NJ, USA.AbstractPURPOSE: Fosaprepitant dimeglumine for injection is the water-soluble phosphorylated prodrug of the neurokinin-1 receptor antagonist aprepitant. Both agents are approved (in combination with a 5-HT3 antagonist and a corticosteroid) for prevention of chemotherapy-induced nausea and vomiting. Because fosaprepitant is likely to be combined and stored in the same intravenous (IV) bag with 5-HT3 antagonists and corticosteroids, the in vitro compatibility of fosaprepitant with these agents and other IV diluents was assessed.
Cancer chemotherapy and pharmacology.Cancer Chemother Pharmacol.2013 Sep;72(3):509-13. doi: 10.1007/s00280-013-2201-2. Epub 2013 Jul 17.
PURPOSE: Fosaprepitant dimeglumine for injection is the water-soluble phosphorylated prodrug of the neurokinin-1 receptor antagonist aprepitant. Both agents are approved (in combination with a 5-HT3 antagonist and a corticosteroid) for prevention of chemotherapy-induced nausea and vomiting. Because
PMID 23860958

Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab.

Krogias C, Hoepner R, Müller A, Schneider-Gold C, Schröder A, Gold R.Author information Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany. christos.krogias@rub.deAbstractIMPORTANCE: A patient with a Caspr2 autoantibodies-associated syndrome had an unusual clinical triad and an excellent response to B-cell-anergizing therapy using the humanized monoclonal antibody tocilizumab directed against the interleukin 6 (IL-6) receptor.
JAMA neurology.JAMA Neurol.2013 Aug;70(8):1056-9. doi: 10.1001/jamaneurol.2013.143.
IMPORTANCE: A patient with a Caspr2 autoantibodies-associated syndrome had an unusual clinical triad and an excellent response to B-cell-anergizing therapy using the humanized monoclonal antibody tocilizumab directed against the interleukin 6 (IL-6) receptor.OBSERVATIONS: A 55-year-old man had an at
PMID 23778873

In vitro trans-scleral iontophoresis of methylprednisolone hemisuccinate with short application time and high drug concentration.

Pescina S, Martini D, Santi P, Padula C, Murtomäki L, Nicoli S.Author information Interdepartmental Center Biopharmanet-TEC, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.AbstractTrans-scleral iontophoresis, i.e. the application of small electric current to enhance drug transport across sclera is an option for non-invasive delivery of corticosteroids to the posterior segment of the eye. In this paper, in vitro trans-scleral iontophoresis of methylprednisolone hemisuccinate was investigated using concentrated drug solutions and short application times to mimic the iontophoretic conditions of in vivo studies. The drug at the donor concentration of 45 mg/ml was delivered through isolated porcine sclera under passive and iontophoretic conditions (cathodal, 2.4 mA) for 2-15 min. In a second set of experiments, the drug was delivered for 5 min at current intensities of 0.9-7.2 mA. After donor removal, drug release was followed up to 24 h. The exposure of concentrated solutions to sclera for 2-15 min under passive conditions caused a notable accumulation of drug up to 0.8 mg/cm², the release of which was successively followed for 24 h. In cathodal iontophoresis, the amount of accumulated drug increased proportionally to the charge between 0.3 and 1.44 Coulomb. When the charge was increased to 2.16 Coulomb by increasing the application time or current intensity, no further enhancement was recorded. This behaviour can be ascribed to substantial drug adsorption on the scleral tissue, as demonstrated through streaming potential studies, with the consequent increase of the electroosmotic flow that opposes drug transport. The set up suggested here could help in defining the optimal conditions for in vivo studies with animal models and reducing the number of in vivo experiments.
International journal of pharmaceutics.Int J Pharm.2013 Jul 15;451(1-2):12-7. doi: 10.1016/j.ijpharm.2013.04.066. Epub 2013 Apr 27.
Trans-scleral iontophoresis, i.e. the application of small electric current to enhance drug transport across sclera is an option for non-invasive delivery of corticosteroids to the posterior segment of the eye. In this paper, in vitro trans-scleral iontophoresis of methylprednisolone hemisuccinate w
PMID 23628405

Japanese Journal

脊髄梗塞にて椎弓形成術を行った１症例

毛利敏朗,池上晃一
中国・四国整形外科学会雑誌 17(2), 271-275, 2005
… Solu-medrol® (methylprednisolone) was started to stabilize swollen tissues. …
NAID 130004438318

Three cases of drug-induced eruption due to Solu-Medrol.

森脇宏人,石井正則,谷口雄一郎,濱田幸雄
耳鼻咽喉科展望 44(2), 120-125, 2001
… We report 3 cases of extremely rare, delayed, drug-induced eruption caused by Solu-Medrol ® …
NAID 130003975223

コハク酸メチルプレドニゾロンナトリウム(ソル・メドロール^【○!R】)による蕁麻疹型薬疹の1例

森晶子,波多野裕二,秀道広,金子栄,山本昇壯
西日本皮膚科 = The Nishinihon journal of dermatology 61(5), 649-652, 1999-10-01
コハク酸メチルプレドニゾロンナトリウム(ソル·メドロール®)による蕁麻疹型薬疹の1例を報告した。23歳の女性。右臀部の悪性軟部腫瘍に対し, 多剤併用化学療法を施行する際にソル·メドロール®を投与した。投与開始約15分後, ほぼ全身に浮腫性紅斑が出現し, 約1時間後に消退した。本剤の再投与試験では膨疹が誘発さ …
NAID 10019140727

Related Pictures

Solu-Medrol® from Pfizer - Buy Online Solu-Medrol - Drug Information and Side Solu-Medrol, Add-O-Vial, 125mg/Vial, SDV Solu – Medrol opinie ,Solu – Medrol Solu-Medrol (for injection) 40mg/1ml Solu-Medrol, Add-O-Vial, 40mg/mL, SDV, 1mL Solu-Medrol 62.5mg/ml inj.pso.1g+16ml